These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 26267722

  • 21. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

  • 22. Tofacitinib for the treatment of moderate-to-severe psoriasis.
    Chiricozzi A, Faleri S, Saraceno R, Bianchi L, Buonomo O, Chimenti S, Chimenti MS.
    Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
    [Abstract] [Full Text] [Related]

  • 23. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [Abstract] [Full Text] [Related]

  • 24. Apremilast as a treatment for psoriasis.
    Shutty B, West C, Pellerin M, Feldman S.
    Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
    [Abstract] [Full Text] [Related]

  • 25. Advances in treating psoriasis in the elderly with small molecule inhibitors.
    Cline A, Cardwell LA, Feldman SR.
    Expert Opin Pharmacother; 2017 Dec; 18(18):1965-1973. PubMed ID: 29171774
    [Abstract] [Full Text] [Related]

  • 26. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED.
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [Abstract] [Full Text] [Related]

  • 27. Current and future oral systemic therapies for psoriasis.
    Kelly JB, Foley P, Strober BE.
    Dermatol Clin; 2015 Jan; 33(1):91-109. PubMed ID: 25412786
    [Abstract] [Full Text] [Related]

  • 28. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M.
    J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
    [Abstract] [Full Text] [Related]

  • 30. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S, Kavanaugh A.
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [Abstract] [Full Text] [Related]

  • 31. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
    Artamonova OG, Karamova AE, Nikonorov AA, Verbenko DA, Vasileva EL, Kubanov AA.
    Bull Exp Biol Med; 2021 May; 171(2):208-211. PubMed ID: 34173094
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM, Tung TH, Wang SH, Chi CC.
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
    Tian F, Chen Z, Xu T.
    J Int Med Res; 2019 Jun; 47(6):2342-2350. PubMed ID: 31096817
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P.
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [Abstract] [Full Text] [Related]

  • 35. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R, Alikhan A.
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [Abstract] [Full Text] [Related]

  • 36. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A, Mahmood F, Wittmann M, Helliwell P.
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [Abstract] [Full Text] [Related]

  • 37. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
    Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R.
    J Drugs Dermatol; 2015 Aug; 14(8):777-84. PubMed ID: 26267721
    [Abstract] [Full Text] [Related]

  • 38. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.
    J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.
    Lancet; 2012 Aug 25; 380(9843):738-46. PubMed ID: 22748702
    [Abstract] [Full Text] [Related]

  • 40. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Zhang J, Tsai TF, Lee MG, Zheng M, Wang G, Jin H, Gu J, Li R, Liu Q, Chen J, Tu C, Qi C, Zhu H, Ports WC, Crook T.
    J Dermatol Sci; 2017 Oct 25; 88(1):36-45. PubMed ID: 28558978
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.